Consensus Natera, Inc.

Stocks

NTRA

US6323071042

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 13:48:04 2026-10-26 EDT			5-day change	1st Jan Change
404.44 ^USD	+0.12%		+1.09%	+76.25%

03:13am	Natera Insider Sold Shares Worth $1,293,246, According to a Recent SEC Filing	MT
10-23	Roth Capital Initiates Coverage on Natera With Buy Rating, $475 Price Target	MT

Evolution of the Average Target: Natera, Inc.

Evolution of the Target Price: Natera, Inc.

Changes in Analyst Recommendations: Natera, Inc.

0cd320228df80.jN8EllWMSg7PaPH_8vxdBbErZRR5vS6CoJIH4Kl-PCc.x4hO2TbNAVf7BqOHgLIKV_V_Fzku6hr1lNpvh_9GY0HmrDPcL-8bRKIpxQ~d68ba68d2343a9533afb8a76e7cb52cf

Analysts' recommendations: Natera, Inc.

10-23	Roth Capital Initiates Coverage on Natera With Buy Rating, $475 Price Target	MT
10-19	Analyst recommendations: ConocoPhillips, Datadog, Intel, Fair Isaac, MGM Resorts…
10-12	Morgan Stanley Adjusts Price Target on Natera to $435 From $355, Maintains Overweight Rating	MT
10-08	Analyst recommendations: Constellation Brands, Etsy, Micron, Palantir, Hilton…
10-06	Analyst recommendations: Nike, AMD, Fair Isaac, Intel, Rambus…
09-25	Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says	MT
09-25	RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating	MT
09-25	Analyst recommendations: 3M Company, Comcast, Quanta Services, Twilio, UiPath…
09-21	Analyst recommendations: Flutter, Constellation Brands, CoreWeave, eBay, Meta Platforms…
09-09	UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating	MT
09-08	Rothschild & Co Redburn Initiates Natera at Buy With $385 Price Target	MT
08-07	RBC Capital Adjusts Price Target on Natera to $350 From $275, Maintains Outperform Rating	MT
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
06-12	Natera MRD Leadership Supported by 'Durable' High-Value Market, RBC Says	MT
04-14	William Blair Initiates Natera at Outperform	MT
03-03	Morgan Stanley Cuts Price Target on Natera to $250 From $265, Keeps Overweight Rating	MT
02-27	UBS Adjusts Natera Price Target to $290 From $280, Maintains Buy Rating	MT
01-07	Citigroup Initiates Natera at Buy With $300 Price Target	MT
12-02	Morgan Stanley Raises Price Target on Natera to $265 From $220, Keeps Overweight Rating	MT
11-18	UBS Adjusts Natera Price Target to $280 From $218, Maintains Buy Rating	MT
11-14	Analyst recommendations: Applied Materials, The Gap, Home Depot, Abercrombie & Fitch…
11-07	America's markets lose their nerve
11-07	Analyst recommendations: AMD, Carmax, Datadog, Instacart, SanDisk…
25-10-12	Natera says to present 14 studies at Esmo, including Imvigor011 oral presentation	RE
25-09-03	RBC Raises Price Target on Natera to $268 From $255, Keeps Outperform Rating	MT

More recommendations

Medical & Diagnostic Laboratories

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NATERA, INC.					+1.84%
	CVS HEALTH CORPORATION					+23.55%
	HCA HEALTHCARE, INC.					-1.54%
	FRESENIUS SE & CO. KGAA					+21.43%
	LABCORP HOLDINGS INC.					+4.92%
	QUEST DIAGNOSTICS INCORPORATED					+5.31%
	TENET HEALTHCARE CORPORATION					+6.69%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+24.34%
	REDE D'OR SÃO LUIZ S.A.					+13.31%
	IHH HEALTHCARE					+29.69%
	Average					+12.95%
	Weighted average by Cap.					+11.50%